The Hill: Achieving an affordable health care future for patients
The drug pricing debate in Washington has kicked back into high gear, and it is more contentious, convoluted and misguided than ever. Who’s on what team? Whose “turn” is next? And, most importantly, what is in the best interest of patients and taxpayers? These questions may sound rhetorical, but they’re questions that Congress should be asking.